Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217364 | 0.82 | ALDH1A1 (0.35) | ADRB2ADRB1ADRB3CASP1ALDH1A1 | |
| SCHEMBL1409148 | 0.82 | ALDH1A1 (0.35) | ADRB2ADRB1ADRB3CASP1ALDH1A1 | |
| SCHEMBL646998 | 0.80 | CASP1 (0.53) | ADRB2ADRB1ADRB3CASP1ALDH1A1 | |
| SCHEMBL10201581 | 0.79 | ADRB2 (0.48) | ADRB2ADRB1ADRB3CASP1ALDH1A1 | |
| SCHEMBL1409757 | 0.74 | ALDH1A1 (0.34) | CASP1ALDH1A1MAPT | |
| SCHEMBL2115719 | 0.73 | CYP3A4 (0.72) | ADRB2ADRB1ADRB3ALDH1A1KDM4E | |
| SCHEMBL646999 | 0.71 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CASP1ALDH1A1 | |
| SCHEMBL6278868 | 0.68 | ADRB2 (0.60) | ADRB2ADRB1ADRB3ALDH1A1KDM4E | |
| SCHEMBL11442214 | 0.67 | ADRB2 (0.56) | ADRB2ADRB1ADRB3ALDH1A1KDM4E | |
| SCHEMBL29268479 | 0.67 | ADRB2 (0.64) | ADRB2ADRB1ADRB3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2295442-A2 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | ADRB2 3689/4885ADRB1 2121/4885ADRB3 3557/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | ADRB2 3689/4885ADRB1 2121/4885ADRB3 3557/4885 |
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | ADRB2 4601/4885ADRB1 3468/4885ADRB3 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.